Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 1,101–1,200 of 10,906
Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy
Arguello, O. A. D., & Haisma, H. J. (2021) · Cancers · doi:10.3390/cancers13071543 · Cited by 84
Paunovska, K., Sanchez, A. J. D. S., Lokugamage, M. P., Loughrey, D., Echeverri, E. S., Cristian, A., Hatit, M. Z. C., Santangelo, P. J., Zhao, K., & Dahlman, J. E. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c03741 · Cited by 80
Nucleic acid therapeutics: Past, present, and future
Naeem, S., Zhang, J., Zhang, Y., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102440 · Cited by 91
Samanovic-Golden, M., Cornelius, A., Wilson, J. P., Karmacharya, T., Gray-Gaillard, S., Allen, J., Hyman, S., Moritz, G., Ali, M., Koralov, S. B., et al. (2021) · medRxiv · doi:10.1101/2021.02.07.21251311 · Cited by 69
mRNA vaccines: Past, present, future
Karam, M., & Daoud, G. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.05.003 · Cited by 94
Liu, C., Lee, J., Ta, C., Soroush, A., Rogers, J. R., Kim, J. H., Natarajan, K., Zucker, J. E., Perl, Y., & Weng, C. (2022) · JMIR Public Health and Surveillance · doi:10.2196/35311 · Cited by 70
Nanotechnology‐Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID‐19 Vaccines
Rinoldi, C., Zargarian, S. S., Nakielski, P., Li, X., Liguori, A., Petronella, F., Presutti, D., Wang, Q., Costantini, M., Sio, L. D., et al. (2021) · Small Methods · doi:10.1002/smtd.202100402 · Cited by 86
Xu, K., Wang, Z., Qin, M., Gao, Y., Luo, N., Xie, W., Zou, Y., Wang, J., & Ma, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113156 · Cited by 100
Mesa, D. O., Hogan, A. B., Watson, O. J., Charles, G. D., Hauck, K., Ghani, A. C., & Winskill, P. (2022) · Communications Medicine · doi:10.1038/s43856-022-00075-x · Cited by 73
Cardiovascular Complications of SARS-CoV-2 Vaccines: An Overview
Shiravi, A. A., Ardekani, A., Sheikhbahaei, E., & Heshmat‐Ghahdarijani, K. (2021) · Cardiology and Therapy · doi:10.1007/s40119-021-00248-0 · Cited by 78
Brufau, S. R., Chopra, A., Ryu, A. J., Gel, E. S., Raskar, R., Kremers, W. K., Anderson, K. S., Subramanian, J., Krishnamurthy, B., Singh, A., et al. (2021) · BMJ · doi:10.1136/bmj.n1087 · Cited by 87
Linking vaccine adjuvant mechanisms of action to function
Ben‐Akiva, E., Chapman, A. P., Mao, T., & Irvine, D. J. (2025) · Science Immunology · doi:10.1126/sciimmunol.ado5937 · Cited by 84
Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2
Petter, E., Mor, O., Zuckerman, N., Oz-Levi, D., Younger, A., Aran, D., & Erlich, Y. (2021) · doi:10.1101/2021.02.08.21251329 · Cited by 71
Haabeth, O. A. W., Lohmeyer, J. J. K., Sallets, A., Blake, T. R., Sagiv-Barfi, I., Czerwinski, D. K., McCarthy, B., Powell, A. E., Wender, P. A., Waymouth, R. M., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00361 · Cited by 77
Nanomaterials for mRNA ‐based therapeutics: Challenges and opportunities
Li, D., Liu, Q., Yang, M., Xu, H., Zhu, M., Zhang, Y., Xu, J., Tian, C., Yao, J., Wang, L., et al. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10492 · Cited by 82
Roadmap to 2030 for Drug Evaluation in Older Adults
Liu, Q., Schwartz, J. B., Slattum, P. W., Lau, S. W. J., Guinn, D., Madabushi, R., Burckart, G. J., Califf, R. M., Cerreta, F., Cho, C., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2452 · Cited by 78
Coggins, S. A., Laing, E. D., Olsen, C. H., Goguet, E., Moser, M. S., Jackson-Thompson, B. M., Samuels, E. C., Pollett, S. D., Tribble, D. R., Davies, J., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab575 · Cited by 79
Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?
Hamady, A., Lee, J., & Loboda, Z. (2021) · Infection · doi:10.1007/s15010-021-01664-z · Cited by 72
SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP
Lee, E., Moreira, M. B., Al-Samkari, H. T., Cuker, A. C., DiRaimo, J. M. , Gernsheimer, T., Kruse, A., Kessler, C. M., Kruse, C., Leavitt, A. D., et al. (2021) · Blood · doi:10.1182/blood.2021013411 · Cited by 69
Arashiro, T., Arima, Y., Muraoka, H., Sato, A., Oba, K., Uehara, Y., Arioka, H., Yanai, H., Kuramochi, J., Ihara, G., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac635 · Cited by 70
Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines
Viswanath, D. I., Liu, H., Huston, D. P., Chua, C. Y. X., & Grattoni, A. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121297 · Cited by 74
Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design
Clemente, B., Denis, M., Silveira, C. P., Schiavetti, F., Brazzoli, M., & Stranges, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1294929 · Cited by 76
Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review
Boroumand, A. B., Forouhi, M., Karimi, F., Moghadam, A. S., Naeini, L. G., Kokabian, P., & Naderi, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940357 · Cited by 76
Nanoparticle stereochemistry-dependent endocytic processing improves in vivo mRNA delivery
Hatit, M. Z. C., Dobrowolski, C. N., Lokugamage, M. P., Loughrey, D., Ni, H., Zurla, C., Sanchez, A. J. D. S., Radmand, A., Huayamares, S. G., Zenhausern, R., et al. (2023) · Nature Chemistry · doi:10.1038/s41557-023-01138-9 · Cited by 76
Striving for Uniformity: A Review on Advances and Challenges To Achieve Uniform Polyethylene Glycol
Bento, C., Katz, M., Santos, M. M. M., & Afonso, C. A. M. (2024) · Organic Process Research & Development · doi:10.1021/acs.oprd.3c00428 · Cited by 89
Recent review of COVID-19 management: diagnosis, treatment and vaccination
Chavda, V. P., Vuppu, S., Mishra, T., Kamaraj, S., Patel, A., Sharma, N., & Chen, Z. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00425-5 · Cited by 76
Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection
Clarke, C., Prendecki, M. F., Dhutia, A., Gan, J. J. L., Edwards, C., Prout, V., Lightstone, L., Parker, E. L., Marchesin, F., Griffith, M. E., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.009 · Cited by 73
He, Z., Le, Z., Shi, Y., Liu, L., Liu, Z., & Chen, Y. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202310401 · Cited by 75
Loomis, R. J., DiPiazza, A. T., Falcone, S., Ruckwardt, T. J., Morabito, K. M., Abiona, O. M., Chang, L. A., Caringal, R. T., Presnyak, V., Narayanan, E., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.772864 · Cited by 75
Self-citationCOVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern
Zeyaullah, M., AlShahrani, A. M., Muzammil, K., Ahmad, I., Alam, S., Khan, W. H., & Ahmad, R. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.693916 · Cited by 77
Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy
Moussion, C., & Delamarre, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101848 · Cited by 87
Protection against Omicron from Vaccination and Previous Infection in a Prison System
Chin, E. T., Leidner, D., Lamson, L., Lucas, K., Studdert, D. M., Goldhaber-Fiebert, J. D., Andrews, J. R., & Salomon, J. A. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2207082 · Cited by 68
Chung, D. J., Shah, G. L., Devlin, S. M., Ramanathan, L. V., Doddi, S., Pessin, M. S., Hoover, E., Marcello, L. T., Young, J. C., Boutemine, S. R., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0139 · Cited by 68
Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types
Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, K. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111106 · Cited by 68
Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery
van der Meel, R., Chen, S., Zaifman, J., Kulkarni, J. A., Zhang, X. R. S., Tam, Y. K., Bally, M. B., Schiffelers, R. M., Ciufolini, M. A., Cullis, P. R., et al. (2021) · Small · doi:10.1002/smll.202103025 · Cited by 74
Leveraging Biological Buffers for Efficient Messenger RNA Delivery via Lipid Nanoparticles
Henderson, M. I., Eygeris, Y., Jozić, A., Herrera‐Barrera, M., & Sahay, G. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00587 · Cited by 82
The COVID-19 Vaccine Is Here—Now Who Is Willing to Get It?
Killgore, W. D. S., Cloonan, S., Taylor, E. C., & Dailey, N. S. (2021) · Vaccines · doi:10.3390/vaccines9040339 · Cited by 74
mRNA therapeutics: New vaccination and beyond
Wei, H. Y., Zheng, L., & Wang, Z. (2023) · Fundamental Research · doi:10.1016/j.fmre.2023.02.022 · Cited by 81
Wright, B. J., Tideman, S., Diaz, G. A., French, T., Parsons, G., & Robicsek, A. A. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00042-x · Cited by 69
Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F. M., Chadwick, D., Clark, R., Cosgrove, C. A., Galloway, J. B., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac803 · Cited by 73
Hsieh, S., Liu, W.-D., Huang, Y., Lin, Y., Hsieh, E.-F., Lian, W., Chen, C., Janssen, R. S., Shih, S., Huang, C., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100989 · Cited by 67
COVID-19 Vaccination in Developing Nations: Challenges and Opportunities for Innovation
Sheikh, A. B., Pal, S., Javed, N., & Shekhar, R. (2021) · Infectious Disease Reports · doi:10.3390/idr13020041 · Cited by 76
Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease
Lynch, S. M., Guo, G., Gibson, D. S., Bjourson, A. J., & Singh, T. (2021) · Cells · doi:10.3390/cells10123367 · Cited by 76
McMurry, R., Lenehan, P., Awasthi, S., Silvert, E., Puranik, A., Pawlowski, C., Venkatakrishnan, A. J., Anand, P., Agarwal, V., O’Horo, J. C., et al. (2021) · Med · doi:10.1016/j.medj.2021.06.006 · Cited by 67
Mittelman, M., Magen, O., Barda, N., Dagan, N., Oster, H. S., Leader, A., & Balicer, R. D. (2021) · Blood · doi:10.1182/blood.2021013768 · Cited by 78
Hou, Y., Lu, K., & Kuo, K. (2021) · Vaccines · doi:10.3390/vaccines9080885 · Cited by 74
The Transcriptional Response to Lung-Targeting Lipid Nanoparticles in Vivo
Radmand, A., Lokugamage, M. P., Kim, H., Dobrowolski, C. N., Zenhausern, R., Loughrey, D., Huayamares, S. G., Hatit, M. Z. C., Ni, H., Cid, A. D., et al. (2023) · Nano Letters · doi:10.1021/acs.nanolett.2c04479 · Cited by 79
Cardoso, R. V., Pereira, P. R., Freitas, C. S., & Paschoalin, V. M. F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122808 · Cited by 76
A New Vaccine to Battle Covid-19
Haynes, B. F. (2020) · New England Journal of Medicine · doi:10.1056/nejme2035557 · Cited by 71
Ou, M. T., Boyarsky, B. J., Chiang, T. P., et al. (2021) · Transplantation · doi:10.1097/tp.0000000000003824 · Cited by 66
Mörz, M. (2022) · Vaccines · doi:10.3390/vaccines10101651 · Cited by 74
Kim, S., Jeon, J. H., Kim, M., Lee, Y., Hwang, Y.-H., Park, M., Li, C. H., Lee, T., Lee, J.-A., Kim, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51411-9 · Cited by 109
Yue, L., Xie, T., Yang, T., Zhou, J., Chen, H., Zhu, H., Li, H., Xiang, H., Wang, J., Yang, H., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27334 · Cited by 75
Trimpert, J., Dietert, K., Firsching, T. C., Ebert, N., Thao, T. T. N., Vladimirova, D., Kaufer, S., Labroussaa, F., Abdelgawad, A., Conradie, A. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109493 · Cited by 68
Callegaro, A., Borleri, D., Farina, C., Napolitano, G., Valenti, D., Rizzi, M., & Maggiolo, F. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26982 · Cited by 64
Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity
van Leeuwen, L. P. M., GeurtsvanKessel, C. H., Ellerbroek, P. M., de Bree, G. J., Potjewijd, J., Rutgers, A., Jolink, H., van de Veerdonk, F. L., Gorp, E. C. M. V., de Wilt, F., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.04.002 · Cited by 71
Young, R. E., Nelson, K. M., Hofbauer, S. I., Vijayakumar, T., Alameh, M., Weissman, D., Papachristou, C., Gleghorn, J. P., & Riley, R. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.11.014 · Cited by 88
Engineering LNPs with polysarcosine lipids for mRNA delivery
Kang, D. D., Hou, X., Wang, L., Xue, Y., Li, H., Zhong, Y., Wang, S., Deng, B., McComb, D. W., & Dong, Y. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.03.017 · Cited by 124
mRNA – A game changer in regenerative medicine, cell-based therapy and reprogramming strategies
Chabanovska, O., Galow, A.-M., David, R., & Lemcke, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114002 · Cited by 83
Hwang, J., Park, S. H., Lee, S. W., Lee, S. B., Lee, M. H., Jeong, G. H., Kim, M. S., Kim, J. Y., Koyanagi, A., Jacob, L., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab592 · Cited by 86
Instructing durable humoral immunity for COVID-19 and other vaccinable diseases
Bhattacharya, D. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.004 · Cited by 67
King, H. A. D., Joyce, M. G., Lakhal-Naouar, I., Ahmed, A., Cincotta, C. M., Subra, C., Peachman, K. K., Hack, H. R., Chen, R. E., Thomas, P. V., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2106433118 · Cited by 67
Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination
Kadire, S. R., Wachter, R. M., & Lurie, N. (2021) · New England Journal of Medicine · doi:10.1056/nejmclde2101987 · Cited by 68
Type-2 Diabetes as a Risk Factor for Severe COVID-19 Infection
Norouzi, M., Norouzi, S., Ruggiero, A. D., Khan, M. S., Myers, S., Kavanagh, K., & Vemuri, R. (2021) · Microorganisms · doi:10.3390/microorganisms9061211 · Cited by 79
Rovida, F., Cassaniti, I., Paolucci, S., Percivalle, E., Sarasini, A., Piralla, A., Giardina, F., Sammartino, J. C., Ferrari, A., Bergami, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26154-6 · Cited by 72
SARS-CoV-2 vaccines for cancer patients: a call to action
Corti, C., Crimini, E., Tarantino, P., Pravettoni, G., Eggermont, A. M. M., Delaloge, S., & Curigliano, G. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.046 · Cited by 71
Zhou, H., Dcosta, B. M., Samanovic, M. I., Mulligan, M. J., Landau, N. R., & Tada, T. (2021) · mBio · doi:10.1128/mbio.01386-21 · Cited by 68
Self-citationAlvim, R. G. F., Lima, T. M., Rodrigues, D. A. S., Marsili, F. F., Bozza, V. B. T., Higa, L. M., Monteiro, F. L. L., de Abreu, D. P. B., Leitão, I. C., Carvalho, R. S., et al. (2022) · Biochemical Engineering Journal · doi:10.1016/j.bej.2022.108537 · Cited by 68
Factors, enablers and challenges for COVID-19 vaccine development
Excler, J., Saville, M. K., Privor-Dumm, L. A., Gilbert, S. E., Hotez, P. J., Thompson, D., Karim, S. S. A., & Kim, J. H. (2023) · BMJ Global Health · doi:10.1136/bmjgh-2023-011879 · Cited by 75
Maringer, Y., Nelde, A., Schroeder, S. M., Schuhmacher, J., Hörber, S., Peter, A., Karbach, J., Jäger, E., & Walz, J. S. (2022) · Science Immunology · doi:10.1126/sciimmunol.add3899 · Cited by 72
Chan, A., Haley, R. M., Najar, M. A., Gonzalez-Martinez, D., Bugaj, L. J., Burslem, G. M., Mitchell, M. J., & Tsourkas, A. (2024) · Nature Communications · doi:10.1038/s41467-024-50235-x · Cited by 81
Zhang, Z., Shen, Q., & Chang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.843928 · Cited by 76
Moore, J. X., Gilbert, K. L., Lively, K. L., Laurent, C., Chawla, R., Li, C., Johnson, R., Petcu, R., Mehra, M., Spooner, A., et al. (2021) · Vaccines · doi:10.3390/vaccines9080879 · Cited by 71
Wang, Z., Cui, K., Costabel, U., & Zhang, X. (2022) · Exploration · doi:10.1002/exp.20210082 · Cited by 67
Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2
Lustig, Y., Nemet, I., Kliker, L., Zuckerman, N., Yishai, R., Alroy-Preis, S., Mendelson, E., & Mandelboim, M. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2104036 · Cited by 67
Connolly, C. M., Ruddy, J. A., Boyarsky, B. J., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220231 · Cited by 67
Lipid nanoparticles for mRNA delivery in brain via systemic administration
Cao, D., Hou, X., Wang, C., Wang, S., Liu, Z., Tian, M., Guo, K., Li, H., Kang, D. D., Zhong, Y., et al. (2025) · Science Advances · doi:10.1126/sciadv.adw0730 · Cited by 91
“The application of LNP-mRNA in treatment and prophylaxis has gained unprecedented advancements, particularly following the rapid development of mRNA vaccines during the COVID-19 pandemic ( 52 , 53 ).”
Noori, M., Nejadghaderi, S. A., Arshi, S., Carson‐Chahhoud, K., Ansarin, K., Kolahi, A., & Safiri, S. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2277 · Cited by 70
Mazzola, A., Todesco, È., Drouin, S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab580 · Cited by 67
Tian, F., Yang, R., & Chen, Z. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27940 · Cited by 73
Chen, M. Z., Yuen, D., McLeod, V. M., Yong, K. W., Smyth, C. H., Herling, B. R., Payne, T. J., Fabb, S. A., Belousoff, M. J., Algarni, A., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01954-9 · Cited by 113
“The successful deployment of two mRNA/lipid nano-particle (LNP) vaccines to combat the COVID-19 pandemic has demonstrated the potential of LNPs to effectively deliver large synthetic mRNA payloads in vivo 2,3 .”
Shem‐Tov, N., Yerushalmi, R., Danylesko, I., Litachevsky, V., Levy, I., Olmer, L., Lusitg, Y., Avigdor, A., Nagler, A., Shimoni, A., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17918 · Cited by 65
Lipid Nanoparticles: A Novel Gene Delivery Technique for Clinical Application
Mashima, R., & Takada, S. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44100341 · Cited by 78
Self-Amplifying RNA: Advantages and Challenges of a Versatile Platform for Vaccine Development
Vallet, T., & Vignuzzi, M. (2025) · Viruses · doi:10.3390/v17040566 · Cited by 89
“These vaccines demonstrated remarkable efficacy in preventing severe illness and reducing virus transmission, with clinical trials showing efficacy rates exceeding 90% [22,23].”
A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs
Bogaert, B., Sauvage, F., Guagliardo, R., Muntean, C., Nguyen, V. P., Pottie, E., Wels, M., Minnaert, A., Rycke, R. M. D., Yang, Q., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.009 · Cited by 71
Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern
Farkash, I., Feferman, T., Saban, N. C., Avraham, Y., Morgenstern, D., Mayuni, G., Barth, N., Lustig, Y., Miller, L., Shouval, D. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110114 · Cited by 63
Havervall, S., Ng, H., Falk, A. J., Greilert‐Norin, N., Månberg, A., Marking, U. W., Laurén, I., Gabrielsson, L., Salomonsson, A., Aguilera, K., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13387 · Cited by 66
Advanced delivery systems for peptide antibiotics
Cesaro, A., Lin, S., Pardi, N., & de la Fuente‐Núñez, C. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114733 · Cited by 75
Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease
Ollila, T. A., Lu, S., Masel, R. H., Zayac, A. S., Paiva, K. J., Rogers, R., & Olszewski, A. J. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.4381 · Cited by 64
A siRNA targets and inhibits a broad range of SARS‐CoV‐2 infections including Delta variant
Chang, Y., Yang, C., Chen, Y., Yang, C., Chou, Y., Chou, H., Chang, T.-Y., Chao, T., Hsu, S., Ieong, S., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202115298 · Cited by 72
A Perspective on Current Flavivirus Vaccine Development: A Brief Review
Dutta, S. K., & Langenburg, T. (2023) · Viruses · doi:10.3390/v15040860 · Cited by 71
Schiaffino, S., Pinker, K., Magni, V., Cozzi, A., Athanasiou, A., Baltzer, P., Herrero, J. C., Clauser, P., Fallenberg, E. M., Forrai, G., et al. (2021) · Insights into Imaging · doi:10.1186/s13244-021-01062-x · Cited by 67
Lee, C.-Y., & Lowen, A. C. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.03.009 · Cited by 76
Gilbert, J., Sebastiani, F., Arteta, M. Y., Terry, A. E., Fornell, A., Russell, R. A., Mahmoudi, N., & Nylander, T. (2024) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2023.12.165 · Cited by 78
Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens
Coughlan, L., Kremer, E. J., & Shayakhmetov, D. M. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.034 · Cited by 71
An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis
Larsen, S. E., Erasmus, J. H., Reese, V. A., Pecor, T., Archer, J., Kandahar, A., Hsu, F.-C., Nicholes, K., Reed, S. G., Baldwin, S. L., et al. (2023) · Vaccines · doi:10.3390/vaccines11010130 · Cited by 66
The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients
Zitt, E., Davidovic, T., Schimpf, J., Abbassi-Nik, A., Mutschlechner, B., Ulmer, H., Benda, M. A., Sprenger-Mähr, H., Winder, T. L., & Lhotta, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.704773 · Cited by 68
Portuguese, A. J., Sunga, C., Kruse‐Jarres, R., Gernsheimer, T., & Abkowitz, J. L. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004957 · Cited by 68
Effectiveness of SARS-CoV-2 vaccination in fully vaccinated solid organ transplant recipients
Malinis, M. F., Cohen, E., & Azar, M. M. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16713 · Cited by 65
Sourij, C., Tripolt, N. J., Aziz, F., Aberer, F., Forstner, P., Obermayer, A. M., Kojzar, H., Kleinhappl, B., Pferschy, P. N., Mader, J. K., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14643 · Cited by 70
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.